Time course of vascular arginase expression and activity in spontaneously hypertensive rats

Life Sciences

Volumn 80, Issue 12, 2007, Pages 1128-1134

  Demougeot, Céline ^a   Prigent Tessier, Anne ^b   Bagnost, Teddy ^a   André, Claire ^c   Guillaume, Yves ^c   Bouhaddi, Malika ^d   Marie, Christine ^b   Berthelot, Alain ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Laboratoire des Sciences Séparatives et Biopharmaceutiques   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Arginase; Hypertension; Nitric oxide; Spontaneously hypertensive rats; Vessels

Indexed keywords

ARGINASE; ARGINASE I; ARGINASE II; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NITRIC OXIDE; TISSUE EXTRACT; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HEMODYNAMICS; HYPERTENSION; INFLAMMATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; ARGINASE; ARGININE; BLOOD PRESSURE; BODY WEIGHT; HYDRALAZINE; HYPERTENSION; INTERLEUKIN-6; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TIME FACTORS;

RATTUS;

EID: 33846922529     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.12.003     Document Type: Article

References (27)

1. Berkowitz D.E., White R., Li D., Minhas K.M., Cernetich A., Kim S., Burke S., Shoukas A.A., Nyhan D., Champion H.C., and Hare J.M. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108 16 (2003) 2000-2006
2. Boos C.J., and Lip G.Y. Is hypertension an inflammatory process?. Current Pharmaceutical Design 12 13 (2006) 1623-1635
3. Boucher J.L., Custot J., Vadon S., Delaforge M., Lepoivre M., Tenu J.P., Yapo A., and Mansuy D. N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochemical and Biophysical Research Communications 203 3 (1994) 1614-1621
4. ω-hydroxy-L-arginine during high-output NO production. American Journal of Physiology 271 5 pt 2 (1996) H1988-H1998
5. Chicoine L.G., Paffett M.L., Young T.L., and Nelin L.D. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. American Journal of Physiology Lung Cellular and Molecular Physiology 287 1 (2004) L60-L68
6. Corraliza I.M., Campo M.L., Soler G., and Modolell M. Determination of arginase activity in macrophages: a micromethod. Journal of Immunological Methods 174 1-2 (1994) 231-235
7. Demougeot C., Prigent-Tessier A., Marie C., and Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. Journal of Hypertension 25 5 (2005) 971-978
8. Durante W., Liao L., Reyna S.V., Peyton K.J., and Schafer A.I. Physiological cyclic stretch directs L-arginine transport and metabolism to collagen synthesis in vascular smooth muscle. FASEB Journal 14 12 (2000) 1775-1783
9. El-Gayar S., Thüring-Nahler H., Pfeilschifter J., Röllinghoff M., and Bogdan C. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. Journal of Immunology 171 9 (2003) 4561-4568
10. Fernandez J., Lopez A.B., Wang C., Mishra R., Zhou L., Yaman I., Snider M.D., and Hatzoglou M. Transcriptional control of arginine/lysine transporter, cat-1, by physiological stress. Journal of Biological Chemistry 278 50 (2003) 50000-50009
11. Gokce N. L-arginine and hypertension. Journal of Nutrition 134 10 Suppl (2004) 2807S-2811S
12. Huynh N.N., and Chin-Dusting J. Amino acids, arginase and nitric oxide in vascular health. Clinical and Experimental Pharmacology and Physiology 33 1-2 (2006) 1-8
13. Ignarro L.J., Buga G., Wie L.H., Bauer P.M., Wu G., and del Soldato P. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 98 7 (2001) 4202-4208
14. Johnson F.K., Johnson R.A., Peyton K.J., and Durante W. Arginase inhibition restores arterial endothelial function in Dahl rats with salt-induced hypertension. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 288 4 (2005) R1057-R1062
15. Lee J., Ryu H., Ferrante R., Morris Jr. S.M., and Ratan R.R. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proceedings of the National Academy of Sciences of the United States of America 100 8 (2003) 4843-4848
16. Lüscher T.F. The endothelium in hypertension: bystander, target or mediator?. Journal of Hypertension 12 10 (1994) S106-S116
17. Nelin L.D., Chicoine L.G., Reber K.M., English B.K., Young T.L., and Liu Y. Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. American Journal of Respiratory Cell and Molecular Biology 33 4 (2005) 394-401
18. Rodriguez S., Richert L., and Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clinical and Experimental Hypertension 22 1 (2000) 75-85
19. Ryoo S., Lemmon C.A., Soucy K.G., Gupta G., White A.R., Nyhan D., Shoukas A., Romer L.H., and Berkowitz D.E. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circulation Research 99 9 (2006) 951-960
20. Sanz-Rosa D., Oubina M.P., Cediel E., de las Heras N., Vegazo O., Jimenez J., Lahera V., and Cachofeiro V. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-κB/IκB system. American Journal of Physiology. Heart and Circulatory Physiology 288 1 (2005) H111-H115
21. Schiffrin E.L. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scandinavian Cardiovascular Journal 47 (1998) 15-21
22. Tenu J.P., Lepoivre M., Moali C., Brollo M., Mansuy D., and Boucher J.L. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3 6 (1999) 427-438
23. Vaziri N.D., Ni Z., and Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneous hypertensive rats. Hypertension 31 6 (1998) 1248-1254
24. Wei L.H., Wu G., Morris Jr. S.M., and Ignarro L. Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 98 16 (2001) 9260-9264
25. Wu G., and Morris Jr. S.M. Arginine metabolism: nitric oxide and beyond. The Biochemical Journal 336 Pt 1 (1998) 1-17
26. Zhang C., Hein T.W., Wang W., Chang C.I., and Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric-oxide-mediated vasodilatory function. FASEB Journal 15 7 (2001) 1264-1266
27. Zhang C., Hein T.W., Wang W., Miller M.W., Fossum T.W., McDonald M.M., Humphrey J.D., and Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44 6 (2004) 1-9